Related Experiment Video
Updated: Sep 17, 2025
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Clinical cancer nanomedicines
Roger M Pallares1, Roman A Barmin1, Alec Wang1
1Institute for Experimental Molecular Imaging, RWTH Aachen University, 52074 Aachen, Germany.
None:
Over the past three decades, nanomedicines have become increasingly common in the treatment of cancer. By altering the pharmacokinetics and biodistribution profiles of drugs, nanomedicines help to reduce toxicity and enhance overall therapeutic indices. This manuscript reviews the current landscape of nanomedicines for cancer therapy, highlighting the formulations that have successfully reached clinical use as well as those being investigated in clinical trials. These formulations include "conventional" nanomedicines that rely on passive drug delivery, as well as newer formulations that are stimuli-responsive, actively targeted, used for combination therapies, or intended to improve immunotherapy. By critically analyzing the clinical progress of nanomedicines, we aim to identify the key features that drive successful translation and lead to clinical impact.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy